

Dear Reviewers,

Thank you for taking your time to review our manuscript. Our responses are below. The changes are indicated in red in the revised manuscript.

02929648 Conclusion: Minor revision

Scientific Quality: Grade B (Very good)

Language Quality: Grade B (Minor language polishing)

Good paper. - Thank you.

03646639 Conclusion: Accept (General priority)

Scientific Quality: Grade B (Very good)

Language Quality: Grade B (Minor language polishing)

This review focuses on advances and updates in the pathology related HCC. Only minor problems exist and deserve exact efforts before the work could be accepted. - Thank you. We re- reviewed the manuscript again and made minor changes accordingly.

04091933 Conclusion: Minor revision

Scientific Quality: Grade B (Very good)

Language Quality: Grade A (Priority publishing)

The topic of the article is very relevant. The authors presented a well-structured manuscript that illuminates the main updates of the pathologic sub-classification of HCC, diagnostic and prognostic role of biomarkers, as well as describing the histopathology of the main subtypes of HCC. References are very relevant. The manuscript can certainly be published, but from my point of view, a minor revision is desirable. It might be worthwhile to discuss briefly the informativity and potential usefulness of some another diagnostic and/or prognostic markers as annexin A2, various glycoproteins (multifucosylated  $\alpha$ -1-acid glycoprotein,  $\alpha$ -1-antitrypsin – SERPINA1, etc.), osteopontin, Golgi protein-73 (GP73), survivin, vascular endothelial growth factor (VEGF), angiopoietin 2. Some of them were already recommended, for example by EASL. In addition, it is desirable to reflect, at least briefly, new approaches to stratify HCC patients using comprehensive molecular evaluation of HCC by multi-platform analysis, e.g. transcriptomics data, genome-scale metabolic networks and network topology/controllability analysis. As examples, please see articles by Bidkhori G. et al., 2018 (doi: 10.1073/pnas.1807305115) and Shimada S. et al., 2018 (doi: 10.1016/j.ebiom.2018.12.058). - A new paragraph about emerging biomarkers and new approaches to stratify HCC and additional references to include these two, are added. Thank you for your suggestion.